Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc.

PCRX

NASDAQHealthcareDrug Manufacturers - Specialty & Generic

Regular session

$24.89

+$0.22 · +0.89%

Aug 24, 10:42 AM ET

PCRX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

54

Fair Value

Momentum

53

Neutral

Sentiment

71

Bullish

Risk resilience

80

Low Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
US
CEO
Frank D. Lee
Listed since
Feb 3, 2011
Employees
827

Market position

Day range

Current $24.89

52-week range

Current $24.89

Open
$24.67
Previous close
$24.67
Volume
49.76K
0.09× average
Average volume
566.48K
Average daily volume
Market cap
979.05M USD
Beta
0.27
Market reference 1
50-day average
$24.8588
+0.13% above average
200-day average
$23.6763
+5.13% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.45B USD
EV / EBITDA
11.83×
Earnings yield
0.61%
Free cash flow yield
11.85%

Profitability & efficiency

Return on equity
1.01%
Return on assets
0.56%
Return on invested capital
1.20%

Financial health

Current ratio
4.54×

Earnings

EPS beat rate
64%
7 beats, 3 misses, 1 met estimate
Average EPS surprise
+3.90%
11 comparable reports
Latest EPS result
0.73
Estimate 0.65 · Beat by 13.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.950.810.670.53Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 0.91, estimate 0.78, surprise +16.67%, Beat. Q2 2025, reported May 8, 2025: actual 0.62, estimate 0.57, surprise +8.77%, Beat. Q3 2025, reported Aug 5, 2025: actual 0.74, estimate 0.72, surprise +2.78%, Beat. Q4 2025, reported Nov 6, 2025: actual 0.7, estimate 0.65, surprise +7.69%, Beat. Q1 2026, reported Feb 26, 2026: actual 0.57, estimate 0.85, surprise -32.94%, Miss. Q2 2026, reported Apr 30, 2026: actual 0.6, estimate 0.61, surprise -1.64%, Miss. Q3 2026, reported Aug 4, 2026: actual 0.73, estimate 0.646, surprise +13.00%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 0.76, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates210.01M193.62M177.23M160.85MQ1 '25BeatQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 187.25M USD, estimate 185.38M USD, surprise +1.01%, Beat. Q2 2025, reported May 8, 2025: actual 168.92M USD, estimate 187.48M USD, surprise -9.90%, Miss. Q3 2025, reported Aug 5, 2025: actual 181.1M USD, estimate 182.38M USD, surprise -0.70%, Miss. Q4 2025, reported Nov 6, 2025: actual 179.52M USD, estimate 201.93M USD, surprise -11.10%, Miss. Q1 2026, reported Feb 26, 2026: actual 196.87M USD, estimate 200.33M USD, surprise -1.73%, Miss. Q2 2026, reported Apr 30, 2026: actual 177.38M USD, estimate 171.8M USD, surprise +3.25%, Beat. Q3 2026, reported Aug 4, 2026: actual 192.4M USD, estimate 191.06M USD, surprise +0.70%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 181.76M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

36 ratings
Strong buy00%
Buy1542%
Hold1747%
Sell411%
Strong sell00%

PCRX news

PCRX peers

ETFs holding PCRX

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research PCRX

research.disclaimer